According to the Zhitong Finance App, Peijia Medical-B (09996) disclosed the 2023 unaudited annual results announcement. The company achieved revenue of 441 million yuan (RMB, same below) during the reporting period, an increase of 75.9% over the previous year. Gross profit of 325 million yuan, an increase of 84.7% year over year. The company's owners should have accounted for a loss of 393 million yuan, and the loss narrowed by 3.7% year-on-year. Loss of $0.58 per share.
During the reporting period, the neurological intervention business achieved revenue of 256 million yuan, an increase of 78.1% over the previous year, which greatly exceeded expectations. The gross profit of this business increased 83.4% year over year to 166 million yuan. The revenue was mainly due to the following: due to the implementation of the company's procurement work in the provinces that won the bid, especially the 21-province alliance collection led by Jilin, the company's spring ring product sales increased significantly; due to the company's professional marketing activities and the rapid decline in neurological interventional surgery with the construction of stroke centers, sales of the company's current and newly approved ischemic and pathway products increased significantly.